Targets › ITGB
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Aug 2028.
Open in Phaseline: the race on ITGB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| TwoStep Therapeutics | TS-104 Peptide-drug conjugate (PDC) delivering monomethyl auristatin E (MMAE) via integrin-target | ITGA, ITGB | Phase 1 | NSCLC (Non-small Cell Lung Cancer) | Aug 2028 |
NSCLC (Non-small Cell Lung Cancer) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.